Ovarian clear cell carcinoma accounts for approximately five to ten percent of American ovarian cancer cases and about 20 percent of cases in Asia, ranking second as the cause of death from ovarian cancer. People with the clear cell subtype typically do not respond well to platinum-based chemotherapy, leaving limited therapeutic options for these patients.
The research by scientists at The Wistar Institute and published online in the journal Nature Cell Biology, demonstrates how a mutation in ovarian clear cell carcinoma can be exploited to design a targeted treatment.
According to the announcement from The Wishtar Institute, “conventional chemotherapy treatments have proven an ineffective means of treating this group of ovarian cancer patients, meaning that alternative strategies based on a person’s genetic makeup must be explored,” said Rugang Zhang, Ph.D., professor and co-program leader in Wistar’s Gene Expression and Regulation Program and corresponding author of the study. “Therapeutic approaches based on the ARID1A mutation have the potential to revolutionize the way we treat these patients.”
Read more about the research and about JKTG’s cancer research collaborative at Wistar.
Featured news
Ted’s Take: What is your role in health and health equity?
As we talk and plan for improvements in virtually anything, it’s important that we examine what our role in that process is and should be.
Ted’s Take: Medicare for all – HUH?
Around every national election, the phrase Medicare for All comes up. My reaction is simple: HUH? Here’s why?
JKTG-Funded Research Tackles Possible Way to Stop Spread of Breast Cancer
New JKTG Foundation-funded research identifies potential new immune system target to head off the spread of breast cancer cells. The work is from the Johns Hopkins Giovanis Institute and appears in the journal Oncogene.
Jayne Koskinas Ted Giovanis
Foundation for Health and Policy
PO Box 130
Highland, Maryland 20777
Media contact: 202.548.0133